pairx faded5.png

Next Generation

Cancer Immunotherapies

About us

PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The PairX platform is built upon a deep understanding of mRNA splicing biology, which when combined with our proprietary antigen and T Cell validation methods yield simultaneous validation of tumor antigen-T Cell pairs in multiple patient derived tumors.

The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab (Founder & CEO of Black Diamond Therapeutics). The company was incubated by Esco Ventures X and spun out from Duke-NUS. The founding investors are Esco Ventures and Avendesora (an investment company represented by Jeffrey Lu and Dr. Timothy Lu).

 
colour%2520pop3_edited_edited.png

Join us in developing next generation cancer immunotherapies.

 
 

Contact us

  • LinkedIn

To learn more, don’t hesitate to get in touch.

info@pairxbio.com

© 2020 by PairX Bio